Angiogenesis is essential to tumor genesis and development, which provides oxygen and nutrition, and is regulated by many factors such as vascular endothelial growth factor receptor (VEGFR), platelet‐derived growth factor receptor (PDGFR) and fibroblast growth factor receptor (FGFR), etc.3, 4Anlotinib AL3818 is a new oral small molecule multitarget tyrosine kinase inhibitor, which can effectively inhibit VEGFR, PDGFR, FGFR, and c‐kit, etc, with broad‐spectrum antiangiogenic and antitumor efficacy.5 This evidence concerns the gene KDR and neoplasm.